The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies
Open accessAbstract
BACKGROUND: Randomised trials have highlighted the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) in high doses and sometimes atypical settings. Here, we provide estimates of the comparative risks with individual NSAIDs at typical doses in community settings. METHODS AND FINDINGS: We performed a systematic review of community-based controlled observational studies. We conducted comprehensive literature searches, extracted adjusted relative risk (RR) estimates, and pooled the estimates for major cardiovascular events associated with use of individual NSAIDs, in different doses, and in populations with low and high background risks of cardiovascular events. We also compared individual drugs in pair-wise (within study) analyses, generating ratios of RRs (RRRs). Thirty case-control studies included 184,946 cardiovascular events, and 21 cohort studies described outcomes in >2.7 million exposed individuals. Of the extensively studied drugs (ten or more studies), the highest overall risks were seen with rofecoxib, 1.45 (95% CI 1.33, 1.59), and diclofenac, 1.40 (1.27, 1.55), and the lowest with ibuprofen, 1.18 (1.11, 1.25), and naproxen, 1.09 (1.02, 1.16). In a sub-set of studies, risk was elevated with low doses of rofecoxib, 1.37 (1.20, 1.57), celecoxib, 1.26 (1.09, 1.47), and diclofenac, 1.22 (1.12, 1.33), and rose in each case with higher doses. Ibuprofen risk was seen only with higher doses. Naproxen was risk-neutral at all doses. Of the less studied drugs etoricoxib, 2.05 (1.45, 2.88), etodolac, 1.55 (1.28, 1.87), and indomethacin, 1.30 (1.19, 1.41), had the highest risks. In pair-wise comparisons, etoricoxib had a higher RR than ibuprofen, RRR = 1.68 (99% CI 1.14, 2.49), and naproxen, RRR = 1.75 (1.16, 2.64); etodolac was not significantly different from naproxen and ibuprofen. Naproxen had a significantly lower risk than ibuprofen, RRR = 0.92 (0.87, 0.99). RR estimates were constant with different background risks for cardiovascular disease and rose early in the course of treatment. CONCLUSIONS: This review suggests that among widely used NSAIDs, naproxen and low-dose ibuprofen are least likely to increase cardiovascular risk. Diclofenac in doses available without prescription elevates risk. The data for etoricoxib were sparse, but in pair-wise comparisons this drug had a significantly higher RR than naproxen or ibuprofen. Indomethacin is an older, rather toxic drug, and the evidence on cardiovascular risk casts doubt on its continued clinical use. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2014) · Medical Entomology and Zoology · Cited by 17,633
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Self-citationComplications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., Tang, J., Rosenstein, R. B., Wittes, J., Corle, D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061355 · Cited by 1,048
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Henry, D., Lim, L. L.-Y., Rodriguez, L. A. G., Gutthann, S. P., Carson, J. L., Griffin, M., Savage, R., Logan, R., Moride, Y., Hawkey, C., et al. (1996) · BMJ · doi:10.1136/bmj.312.7046.1563 · Cited by 827
Self-citationSchneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
Catella-Lawson, F., McAdam, B., Morrison, B. W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K. C., Quan, H., Gertz, B. J., & Fitzgerald, G. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 597
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Schjerning Olsen, A.-M., Fosbøl, E. L., Lindhardsen, J., Folke, F., Charlot, M., Selmer, C., Lamberts, M., Bjerring Olesen, J., Køber, L., Hansen, P. R., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004671 · Cited by 335
Golder, S., Loke, Y. K., & Bland, M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001026 · Cited by 269
Ombardier, C. L. B., Aine, L. O. L., Eicin, A. L. R., Hapiro, D. E. S., Urgos, R. U. B., Avis, B. A. D., Ay, R., Arcos, M. J., Erraz, B. O. F., Awkey, C. H. J. H., et al. (2010) · Cited by 253
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis
Caldwell, B. O. (2006) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.99.3.132 · Cited by 221
Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
García Rodríguez, L. A., Varas-Lorenzo, C., Maguire, A., & González-Pérez, A. (2004) · Circulation · doi:10.1161/01.cir.0000132491.96623.04 · Cited by 221
Helin-Salmivaara, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl053 · Cited by 211
Non‐Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction
Hernández‐Díaz, S., Varas‐Lorenzo, C., & García Rodríguez, L. A. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_302.x · Cited by 201
Rubin, B. R., Burton, R., Navarra, S., Antigua, J., Londoño, J., Pryhuber, K. G., Lund, M., Chen, E., Najarian, D. K., Petruschke, R. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20007 · Cited by 188
Fosbøl, E. L., Folke, F., Jacobsen, S., Rasmussen, J. N., Sørensen, R., Schramm, T. K., Andersen, S. S., Rasmussen, S., Poulsen, H. E., Køber, L., et al. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.861104 · Cited by 167
Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer
Kerr, D. J., Dunn, J., Langman, M. J. S., Smith, J. L., Midgley, R. S., Stanley, A., Stokes, J. C., Julier, P., Iveson, C., Duvvuri, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071841 · Cited by 133
MacDonald, T. M., Morant, S. V., Goldstein, J. L., Burke, T. A., & Pettitt, D. (2003) · Gut · doi:10.1136/gut.52.9.1265 · Cited by 110
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors
Lévesque, L. E. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051679 · Cited by 68
García Rodríguez, L. A., González-Pérez, A., Bueno, H., & Hwa, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016780 · Cited by 59
Further experience with indomethacin in the treatment of rheumatic disorders.
Thompson, M., & Percy, J. S. (1966) · BMJ · doi:10.1136/bmj.1.5479.80 · Cited by 44
Lúcio, M., Ferreira, H., Lima, J. L. F. C., & Reis, S. (2006) · Medicinal Chemistry · doi:10.2174/157340606778250199 · Cited by 40
Barozzi, N., & Tett, S. E. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1451 · Cited by 31
Cited by
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Self-citationAdvances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology
Altman, R., Bosch, B., Brune, K., Patrignani, P., & Young, C. (2015) · Drugs · doi:10.1007/s40265-015-0392-z · Cited by 493
New insights into the use of currently available non-steroidal anti-inflammatory drugs
Brune, & Patrignani, P. (2015) · Journal of Pain Research · doi:10.2147/jpr.s75160 · Cited by 469
McGettigan, P., & Henry, D. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001388 · Cited by 414
Self-citation
Metadata
- Authors
- McGettigan, P., & Henry, D.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-09-27
- Volume
- 8
- Issue
- 9
- Pages
- e1001098
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W1993961357
- Cited by
- 571
- References
- 32
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.